Most life sciences companies believe they have a value proposition. Few actually do.

What they have is a collection of technical assertions — performance specifications, process advantages, yield improvements, purity benchmarks — that the internal team has internalized as fact and mistakes for commercial argument. The distinction matters enormously. A technical assertion tells a buyer what something does. A value proposition tells a buyer why they should care, what problem it solves for them specifically, and why your solution solves it better than the alternative they are already using or considering.

The gap between those two things is where most commercial launches quietly fail.

What a Value Proposition Actually Is

A value proposition is a structured, externally-oriented argument for why a specific buyer, in a specific role, at a specific type of organization, should choose your offering over available alternatives. It is not a tagline. It is not a feature list. It is not a mission statement dressed in commercial language.

It answers eight questions — and the answers must be validated, not assumed:

Working through these questions sounds straightforward. It rarely is. The unmet need is almost always more nuanced than the internal team believes. The competitive solution is almost always more entrenched. The differentiator is almost always less unique than assumed. And the claims — the part that actually drives buyer confidence — are almost always less substantiated than they need to be.

Why This Is Harder Than It Looks

The value proposition challenge in life sciences has a specific texture that general commercial frameworks underestimate.

Technical teams in bioprocessing, cell and gene therapy, clinical diagnostics, and medical devices know their science completely. They have lived with it through development, iteration, and refinement. That deep internalization is an asset in the lab. In a commercial context, it becomes a liability — because what is self-evident to the people who built the product is not self-evident to the buyer who is being asked to adopt it, change their workflow, justify the spend to procurement, and stake their credibility on the decision.

The translation from technical to commercial is not a communication problem. It is a strategic problem. It requires extracting the commercial meaning from technical fact — and that extraction is resisted, consciously or not, by the teams who built the product. They have already done the work. They know it is good. The idea that it needs to be explained differently for a commercial audience can feel like a challenge to the work itself.

This is the friction point that derails value proposition development more than any other. It requires structured interrogation — not of the product, but of the assumptions the team has built around it.

Our Approach to Refracting Insights

At MKA, our focus is on delivering clarity — commercial clarity that an entire organization can execute from. What we do, fundamentally, is refract: we take the dense, internalized knowledge that exists across every function of an organization and bend it into something commercially visible, directional, and actionable.

This happens at a specific moment in the product lifecycle — after development is substantially complete, before commercial launch begins. It is the transition step most organizations skip, moving directly from “the product is ready” to “let’s go to market” without stopping to build a coherent, aligned picture of what they actually have.

We pull the meaningful knowledge that exists across every function — R&D, manufacturing, regulatory, commercial, leadership — into a single consolidated view. Every team member sees the product through their own lens. The scientist sees the mechanism. The manufacturing lead sees the process advantage. The regulatory team sees the clearance pathway. The sales lead sees the customer pain point. None of those views is wrong. None of them alone is sufficient.

What we are doing is effectively a structured post-mortem of the development journey — not to evaluate what went right or wrong, but to extract what each function knows, believes, and has experienced, and assemble it into the strongest and most complete picture of what the product is and why it matters.

The most valuable output is not the document that emerges. It is the organizational alignment it creates.

We have worked with organizations three and four years after a product launch — or after an acquisition — where the commercial narrative had quietly fractured. Sales was carrying one version of the story. Marketing had built assets around another. Leadership was operating from a third. No single version was entirely wrong. But none of them was the whole. And the fracture, invisible from the outside, was driving real organizational damage — stalled sales cycles, inconsistent customer conversations, seller disengagement, and a quiet but persistent refusal by parts of the commercial team to carry a message they did not believe in.

Organizational behavior runs counter to the current when belief is not present. A sales organization that does not own the story will not tell it — not because they are resistant, but because the story was never built with them or for them.

By pulling every function into building the commercial picture — by making each contributor’s knowledge and experience visible and valued — shared ownership of the narrative emerges. A fifty-person sales organization that can see their own experience reflected in the story will carry that message with conviction. That conviction is not a soft outcome. It is the difference between a commercial team that executes and one that hedges.

This is where what we deliver goes beyond commercial strategy. We function as organizational diagnosticians — listening across functions, surfacing the disconnects that internal teams are too close to see, and generating the alignment that makes commercial execution possible.

The Most Common Failure Mode

The single most destructive pattern in life sciences commercial launches is hiring a brand agency before the value proposition is solid.

It happens more often than it should. The product is ready. Leadership wants to see commercial momentum. A creative agency is engaged. Positioning workshops are conducted. A visual identity is developed. A launch campaign is built.

And it falls flat — because the foundation was hollow. The agency built aesthetics around assertions that were never validated. The messaging sounds polished but does not connect. The sales team cannot use it because it does not map to what buyers actually ask about. The campaign generates impressions but not conversations.

The brand agency trap is not the agency’s fault. It is a sequencing failure. Creative work amplifies what is already there. If what is there is technically accurate but commercially untranslated, amplification makes the problem more expensive, not less visible.

MKA Strategic Implication

The value proposition is not the first step in a commercial launch checklist. It is the strategic foundation that determines whether every subsequent investment in messaging, content, sales enablement, and campaign spend will generate return or reinforce confusion. In our experience working with mid-market life sciences companies, the organizations that compress or skip value proposition development do not save time — they lose it, compensating downstream for a gap that should have been closed at the start.

What a Strong Value Proposition Enables

When the value proposition is validated and organizational alignment is established, three things become immediately possible:

A messaging strategy can be built with confidence — because the commercial argument is clear, the personas are defined, and the claims are substantiated.

A sales enablement program can be built with specificity — because sellers know what problem they are solving, for whom, against what alternative, and with what evidence.

A content strategy can be built with purpose — because every asset has a validated argument to amplify rather than a hollow assertion to dress up.

The value proposition is where commercial clarity begins. Everything that follows is execution against it.